Who are Ciprofloxacin Tablets & Metronidazole tablets's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ciprofloxacin-tablets-metronidazole-tablets.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Ciprofloxacin Tablets & Metronidazole tablets — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Ciprofloxacin Tablets & Metronidazole tablets (Ciprofloxacin Tablets & Metronidazole tablets) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Fluoroquinolone + Nitroimidazole antibiotic combination. Area: Infectious Disease.

marketed Fluoroquinolone + Nitroimidazole antibiotic combination Bacterial DNA gyrase, topoisomerase IV (ciprofloxacin); anaerobic DNA (metronidazole) Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Ciprofloxacin Tablets & Metronidazole tablets (Ciprofloxacin Tablets & Metronidazole tablets) — MinaPharm Pharmaceuticals. This combination product uses ciprofloxacin to inhibit bacterial DNA gyrase and topoisomerase IV, while metronidazole generates reactive intermediates that damage DNA in anaerobic microorganisms.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Ciprofloxacin Tablets & Metronidazole tablets TARGET	Ciprofloxacin Tablets & Metronidazole tablets	MinaPharm Pharmaceuticals	marketed	Fluoroquinolone + Nitroimidazole antibiotic combination	Bacterial DNA gyrase, topoisomerase IV (ciprofloxacin); anaerobic DNA (metronidazole)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Fluoroquinolone + Nitroimidazole antibiotic combination class)

MinaPharm Pharmaceuticals · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Ciprofloxacin Tablets & Metronidazole tablets — Competitive Intelligence Brief. https://druglandscape.com/ci/ciprofloxacin-tablets-metronidazole-tablets. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab